Novavax (NVAX)
(Real Time Quote from BATS)
$11.72 USD
-0.34 (-2.82%)
Updated Jul 9, 2024 03:44 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
NVAX 11.72 -0.34(-2.82%)
Will NVAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVAX
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
Other News for NVAX
Meme Stock or Vaccine Stock? Novavax’s Identity Crisis and Why It Matters for Investors
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Decoding Novavax's Options Activity: What's the Big Picture?
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Insider Sale: Director James Young Sells Shares of Novavax Inc (NVAX)